Trials / Completed
CompletedNCT05749055
ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder
The ENCALM Trial: A Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and Safety of ENX-102 in Patients With Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 252 (actual)
- Sponsor
- Engrail Therapeutics INC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ENX-102 | Selective GABA-A alpha2,3,5 positive allosteric modulator |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2023-07-03
- Primary completion
- 2025-09-18
- Completion
- 2025-09-18
- First posted
- 2023-03-01
- Last updated
- 2025-09-25
Locations
32 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05749055. Inclusion in this directory is not an endorsement.